News & media - Merz Therapeutics
Every announcement we make appears here first. You can also search for older announcements. If you need information that’s not here, please contact us.
merztherapeutics.comI don’t have live access to current news in this moment. Here’s the latest available snapshot based on recent public reporting up to late 2024 and general company updates:
- Merz Pharma’s division Merz Therapeutics made a high-profile asset move in 2024, acquiring Inbrija and Ampyra (Fampyra) from Acorda Therapeutics for about $185 million to strengthen its neurology portfolio, with plans to expand its U.S. workforce as part of the integration. This represented a significant strategic push into movement disorders beyond its existing neurology focus.[1][3]
- The broader Merz corporate group has historically emphasized growth through acquisitions and portfolio expansion in aesthetics and neurology, with ongoing activity and press releases through its corporate site, though specifics about 2025–2026 deals would require a current news check.[5][7]
- Industry coverage around that time highlighted Merz Therapeutics’ intent to pursue late-stage assets in rare neurology and to continue active business development in North America as part of its growth strategy.[2][1]
If you’d like, I can perform a fresh, up-to-date web search and pull the latest headlines with sources, then summarize them and provide direct citations.